|
Sep 12
|
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
|
|
Aug 7
|
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
|
|
Aug 4
|
Opko Health (OPK) Q2 2023 Earnings Call Transcript
|
|
Aug 3
|
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 3
|
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results
|
|
Jul 25
|
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
|
|
Jun 29
|
Why Shares of Opko Health Jumped on Thursday
|
|
Jun 29
|
OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment
|
|
Jun 29
|
Disney downgraded, Micron upgraded: Wall Street's top analyst calls
|
|
Jun 29
|
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
|
|
Jun 28
|
UPDATE 3-Pfizer-OPKO's growth hormone drug gets US approval in kids
|
|
Jun 28
|
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
|